Haemoctin

Haemoctin is a human coagulation factor VIII concentrate supplied as an intravenous preparation. It contains the active ingredient human factor VIII and is used in the European market as a prescription product for replacement therapy in patients with factor VIII deficiency. The product is administered under medical supervision and is indicated for management of bleeding episodes, surgical prophylaxis, and acquired factor VIII deficiency. Haemoctin is formulated without animal-derived proteins.

Haemoctin is indicated for several clinical situations where factor VIII replacement is required.

- Treatment of acute bleeding episodes in patients with hemophilia A. - Routine prophylaxis to prevent spontaneous bleeds in severe hemophilia A. - Surgical prophylaxis for patients undergoing invasive procedures. - Management of acquired factor VIII deficiency associated with inhibitors or autoimmune conditions. - Use in combination with other hemostatic agents as directed by a hematologist. - Perioperative management to maintain adequate factor levels during and after surgery.

Adverse reactions to Haemoctin may vary in frequency and severity.

Common: - Headache. - Fever or chills. - Nausea. - Injection site reactions such as erythema or swelling. - Transient increase in blood pressure.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events including deep vein thrombosis. - Hemolysis or renal impairment. - Severe hypotension.

Healthcare providers should consider several precautions before prescribing Haemoctin to ensure safe use.

- Assess for a history of inhibitors to factor VIII. - Evaluate for hypersensitivity to any component of the product. - Monitor for signs of thrombosis, especially in patients with risk factors. - Use caution in patients with cardiovascular disease or hypertension. - Adjust dosage in renal or hepatic impairment as clinically indicated. - Avoid use in patients with known severe allergic reactions to plasma-derived products.

Haemoctin may interact with other medications that affect coagulation or immune response.

Avoid: - Concurrent use of other factor VIII concentrates without medical supervision. - Administration of antifibrinolytic agents at high doses without monitoring.

Use with caution: - Immunosuppressive therapies that may alter inhibitor development. - Concomitant anticoagulants such as warfarin or direct oral anticoagulants, requiring close monitoring of coagulation parameters. - Vaccines, particularly live attenuated vaccines, may require timing adjustments. - Other hemostatic agents, including recombinant activated factor VII, should be coordinated by a specialist.